Monoclonal antibodies no better than placebo for early Parkinson disease

The monoclonal antibodies cinpanemab and prasinezumab show almost no benefit for early Parkinson disease, according to two phase 2 trials published in the Aug. 4 issue of the New England Journal of Medicine.

This post was originally published on this site